U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. FDA/OCE Public Meeting on Relevant Molecular Targets in Pediatric Cancers: Applicability to Therapeutic Investigation FDARA 2017
  1. News & Events for Human Drugs

Meeting

Event Title
FDA/OCE Public Meeting on Relevant Molecular Targets in Pediatric Cancers: Applicability to Therapeutic Investigation FDARA 2017
April 20, 2018


Date:
April 20, 2018
Time:
04:00 AM - 11:30 AM EDT


Date:

April 20, 2018

Time:

8:00 a.m. to 3:30 p.m.

Location:

FDA White Oak Campus
Building 31
White Oak Great Room A
10903 New Hampshire Avenue
Silver Spring, Maryland

Public Meetings at the FDA White Oak Campus:

Public Meeting Attendee Information is provided in the following link.
https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm

Topic for Discussion:

The FDA Oncology Center of Excellence will hold a public meeting to review and discuss a provisional list of molecular targets to which drugs are being developed for adult cancer indications but which may also be relevant to the growth and/or progression of a cancer which occurs predominantly in children thereby providing a possible rationale for early pediatric evaluation. This meeting is intended for multi-stakeholder participation and input to the Food and Drug Administration as it responds to its FDARA mandate to develop, post on the FDA website, and update regularly such a list to guide sponsors as to which molecular mechanism of action-specific targeted cancer drugs might be considered for early evaluation in children. This list is envisioned to guide sponsors in decisions related to the development of initial Pediatric Study Plans and reaching agreement with the Agency in advance of their new NDA or BLA submissions. In addition to creating the required list, FDA welcomes discussion of additional considerations, including international collaboration, which may be necessary when evaluating the scientific rationale and feasibility of pediatric investigations in response to the amended Pediatric Research Equity Act (PREA) requirements for assessment of molecularly targeted cancer drugs in children. Further input is sought in developing transparent approaches to prioritization of new targeted drugs, particularly of those in the same class where multiple studies in a rare population of patients may neither be necessary or possible.

Meeting Materials:

Webcast Information:

https://collaboration.fda.gov/pediatricworkshop/

Registration Link:

Please use the following link to register for this meeting. You will receive additional information about the meeting and an agenda closer to the date of the meeting via email. Please note that you will not receive an email confirming your registration.

Registration for Relevant Molecular Targets in Pediatric Cancerdisclaimer icon

Contact:

Christine Lincoln
Christine.Lincoln@fda.hhs.gov